Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis, para-aortic lymph node metastasis, locally advanced rectal cancer, combined organ resection, and the association between obesity and colorectal cancer. Prof. Toh Han Chong from the National Cancer Centre Singapore (NCCS) attended the conference.
Professor Lin Yuehui: Advances and Strategies in Targeted Therapy for Acute Leukemia | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

Professor Lin Yuehui: Advances and Strategies in Targeted Therapy for Acute Leukemia | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.
Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.
Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical diagnostic and treatment experience, and future directions in the discipline, creating a professional event of high academic caliber, strong clinical relevance, and significant industry influence.
Professor Wu Tong: Exploring the “Gaobo Model” of Hematopoietic Stem Cell Transplantation Strategies | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

Professor Wu Tong: Exploring the “Gaobo Model” of Hematopoietic Stem Cell Transplantation Strategies | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

To further advance both scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a high-level academic event with strong clinical and industry impact.
Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish a high-level academic exchange platform, the 2026 Boren Precision Hematologic Oncology Conference officially opened in Beijing on May 16 in a hybrid online-offline format. The conference was jointly hosted by the Beijing Association for the Promotion of Integrated Traditional Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering.
PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

In the previous episode, we reviewed the full evolution of the HOPE series from HOPE-01 through HOPE-04. Among all its design features, one detail may represent the most distinctive — and perhaps boldest — aspect of the HOPE program within the global bladder-preservation landscape: its enrollment criteria.
PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

In the previous episode, we explored the clinical rationale and technical safeguards behind the expanded enrollment criteria of HOPE-02/03. In this installment, we place HOPE-02 within the broader landscape of perioperative and bladder-preservation research in muscle-invasive bladder cancer (MIBC) to better understand its position among contemporary global studies.